U.S. regulator may approve Pfizer vaccine booster dose for 16-17-year-olds

According to the WSJ, such a step is associated with growing concern about the spread of the omicron strain of coronavirus.

The U.S. Food and Drug Administration (FDA) may next week allow the use of a booster dose of the Pfizer – BioNTech consortium vaccine for people aged 16 and 17 years. This was reported by The Wall Street Journal newspaper, citing a source familiar with the regulator’s plans.

According to the publication, such a move by the regulator is associated with growing concern about the spread of the omicron strain of coronavirus.

Previously, the FDA approved the use of a booster dose of Pfizer – BioNTech vaccine for people aged 18 years and older. The booster dose will be available at least six months after the introduction of the second component of the vaccine.

Last week, the World Health Organization (WHO) designated the strain of coronavirus B.1.1.529, found in southern Africa, with the Greek letter “Omicron.” The WHO statement said that this variety “has a large number of mutations, a number of which are of concern.” Several changes in the spike protein at once can potentially make it difficult to neutralize the pathogen with antibodies, which can affect the effectiveness of vaccines. In addition, according to preliminary data, the strain has an increased ability to spread.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Author: Ivan Maltsev
The study of political and social problems of different countries of the world. Analysis of large companies on the world market. Observing world leaders in the political arena.
Function: Chief-Editor
E-mail: Great7news@gmail.com
Ivan Maltsev

Spelling error report

The following text will be sent to our editors: